FDA Approved: PHYRAGO — Supplemental Application (Cycle Pharmaceuticals Ltd)

View source ↗

Summary

FDA approved a supplemental application for PHYRAGO (dasatinib) submitted by Cycle Pharmaceuticals Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• PHYRAGO (DASATINIB)

Snippet

SUPPL AP for PHYRAGO (DASATINIB)